

Index

a

(-)- α -bisabolol, 540–541
ginger extract/gingerols, 543–546
acetaminophen, 333
aquaporin-3 (AQP3), 418
ACTH (adrenocorticotropine), 115
actin, 117
AcTP11 (N-acetyl-Pro-Pro-Tyr-Leu), 295–296
studies, epidermis cohesion
on syndecan-1 and type XVII
collagen, 296–298, 301–303
results, 298–301
adenosine 5'-triphosphate. See ATP
adipose tissue, 571–572
adrenocorticotropine. See ACTH
advertising cosmetics. See cosmetic claims
Advertising Standards Association, UK, 40
aging. See antiaging process/products
AHAs (alpha hydroxy acids), 8
exfoliation, 271–272
irritation risks, 280
skin lightening, 332
alopecia, 591
alpha hydroxy acids. See AHAs
alpha2beta1 integrins and vinculin, 481, 484
alphahydroxy fatty acid ceramide, 419
alpha-S2 casein precursor, 103
alpha-SMA, 481–482, 485–486
ECM stimulation, 478
mechano-receptors, 477–479
alpha-tocopherol. See vitamin E
 α -melanocyte-stimulating hormone.
See α -MSH

amino acids
antiaging products, 99–100
ATP (adenosine 5'-triphosphate), 104–105
from milk, 103–104
RGS amino acids, 104–105
SNAP amino acids, 105–106
coded, 111
in cosmetics, 112
definition, 110
essential, 111–112
manufacturing, 110–111
natural, 111
origin, 110–111
 α -MSH (α -melanocyte-stimulating hormone)
POMC (pro-opiomelanocortin), 405, 406
angiotensin, 113
animal testing, 28
alternatives, assessing skin corrosion potential, 28–31
Draize rabbit skin test, 28–30
OECD (Organization for Economic Co-Operation and Development), 29–30
antiaging process/products, 122
aging levels, 491–492
amino acids, 99–100
ATP (adenosine 5'-triphosphate), 104–105
from milk, 103–104
RGS amino acids, 104–105
SNAP amino acids, 105–106
antiaging, definition, 507

- antiaging actives
 - botanicals, 510–511
 - definition, 506–507
 - enzymes, 511–513
 - vitamins, 507–510
- cell senescence, 122
 - CDK (cyclin-dependent kinase) inhibitor, 123
 - peptides, 102
 - p53/p21/p16ink4a pathway, 123–124
 - SA-b-gal (senescence-associated b-galactosidase) enzyme, 124–125
 - SIPS (Stress-induced Premature Senescence), 123
 - telomere shortening, 122–123
- delivery and dosage links, 17
- dermatologist and cosmetic chemist links, 18
- DNA-Na
 - keratinocytes and fibroblasts, 494–497
- expression and gravity wrinkles, 476
- γ -PGA (γ -poly glutamic acid), 443–446
 - γ -PGA hydrogel, 449–450, 451
 - hair applications, 450–453
 - skin applications, 446–449
- HA (hyaluronic acid), 84, 455–456
 - SHA (sodium hyaluronate), 455
 - SHAB (sodium hyaluronate, fermentation of *Bacillus subtilis*), 457–463
- IPIS (isopropyl isostearate) and ISIS (isostearyl isostearate), 428–432
- lipids in multi-lamellar systems, studies, 419–425
- mechanical resistance, 475–477
 - alpha2beta1 integrins and vinculin, 481, 484
 - alpha-SMA, 481–482, 485–486
 - alpha-SMA and mechano-receptors, 477–479
 - fibroblasts and ECM interactions, 476, 479
 - rye extract, 479–488
- mechanisms of action
 - barrier function enhancement, 14
 - cellular communication regulation, 16
 - cellular messenger provision, 16
 - cellular repair, 15–16
 - exfoliation increase, 14–15
 - inflammation decrease, 15–16
 - oxidation inhibition, 15–16
 - photoprotection delivery, 16
 - pigmentation modulation, 16
 - receptor activation, 14
- peptides, 99–100
 - alpha-S2 casein precursor, 103
 - cell senescence, 102
 - fusion peptides, 106–107
 - GHK-Cu peptides, 100
 - KTTKS peptides, 100–101, 106–107
 - LKKTET polypeptides, 100
 - manufacturing, 111
 - origin, 111
 - Tat peptides, 106
 - thymosin beta4 peptides, 104
- sodium DNA, 493–494
 - formulas, 498–499
 - keratinocytes and fibroblasts, 494
- UV-induced symptom treatments, 513
 - barrier repairs, 514–515
 - tissue repairs, 515–517

- antibodies, 118, 119
- antidandruff efficacy
- CT (coal tar), 617–620, 621
 - SSOS (sodium shale oil sulfonate), 618, 620–623
 - studies/results with SSOS and CT, 623–631
- anti-freckle studies, 371–372
- APoB protein silencing, 24
- AQP3 (aquaporin-3), 418, 423
- arabinoxylans, 480
- arachidonic acid, 604, 606–610
- arbutin, 329–330, 340, 347–348
- ascorbic acid. See vitamin C
- asparagus extract, 336
- aspartic proteases, 263
- α -tocopherols, 524–525
- ATP (adenosine triphosphate), 104–105, 181
 - mitochondria, 139–140, 170
- avenanthramides
- natural: A, B and C, 550–551
 - synthetic
 - avenanthramide D and E, 551–552
 - dihydroavenanthramide D and E, 551–552
 - studies/results, 552–563
- avobenzone, 15
- azelaic acid, 330
- B**
- B16 melanocytes, tyrosinase inhibitors, 345–346, 347
- PEAS and actives, efficacy, 354–358
- base excision repair (BER), 172
- BCA assay (bicinchoninic acid assay), 150
- β -endorphins, 405–406
 - chaste tree berry extracts, 406–407
 - benzoyl peroxide, 84
- BER (base excision repair), 172
- BFV (blood flow volume), 221, 222, 225
- bicinchoninic acid assay (BCA assay), 150
- biostatistics, claims, 40, 45
- Biotinoyl-Gly-His-Lis, 116
- black cohosh extract, 336
- blood flow volume (BFV), 221, 222, 225
- body contouring
- mesotherapy, 572–573
 - skin structure, 567–568
 - slimming treatments
 - adipose tissue, 571–572
 - connective tissue, 570–571
 - microcirculation, 569–570
- borage oil, 310
- botanicals, 510–511
- bradykinin, 113
- Broadcast Advertising Clearance Centre, UK, 40
- C**
- canola oil liquid emollient. See COLE
- capacitance, skin, 221, 224, 225
 - Corneometer measurements, 427
- carnitine, 112
- catalase and UV radiation
- damage prevention, 511–513
 - oxidative stress, 147–149, 151–152
- Cdel (common deletion), mtDNA, 143–145
- CDK (cyclin-dependent kinase) inhibitor, 123
- cDNA (complementary deoxyribonucleic acid), 181
- cell senescence, 122
 - CDK (cyclin-dependent kinase) inhibitor, 123

- p53/p21/p16ink4a pathway, 123–124
- SA-b-gal (senescence-associated b-galactosidase) enzyme, 124–125
- SIPS (Stress-induced Premature Senescence), 123
- telomere shortening, 122–123
- cellulite, 567–568
- chaste tree berry extracts
 - acetyl tyrosine, 407–412
 - β-endorphin-like compounds, 406–407
- chemokines, 118
- citrullus lanatus. *See* watermelon extract
- CLA (conjugated linoleic acid), 604–605
- CLA glutathione, 606–609
- claims. *See* cosmetic claims
- CLASH-DNA (CLA glutathione and sodium DNA), 609–614
- CL-SB (cross-linking subtilisin), 267–269, 273–275
- coal tar. *See* CT
- COLE (canola oil liquid emollient), 525
 - anti-inflammation properties, 530
 - oxidation stability, 525–526
 - protection against photooxidation, 526–527
 - on skin cultures, 527–530
 - sun care examples, 530–532
- COLIPA (Cosmetic, Toiletry, and Perfumery Association), 50
- collagen
 - amino acids, 112
 - collagen fibrils, 128
 - peptides, 111
 - proteins, 117
 - type XVII collagen, 295
 - studies/results of effect of AcTP11, 296–304
 - collagen I synthesis, 242–244
 - collagenase-1. *See* MMP-1
 - common deletion (Cdel), mtDNA, 143–145
 - conjugated linoleic acid. *See* CLA
 - connective tissue (CT), 570–571
 - copper peptides, 15
 - CoQ10 (coenzyme Q10), 141–146
 - Corneometer measurements
 - on IPIS and ISIS, 437–439
 - versus NIR (near-infrared reflectance) spectroscopy, 428–432
 - skin capacitance, 427
 - cosmeceuticals
 - definition, 5–6
 - Proposed Rules for Sunscreens, 8
 - Cosmetic, Toiletry, and Perfumery Association. *See* COLIPA
 - cosmetic claims
 - developing, 35–36
 - skin tightening, 470
 - indentometric testing, 470–473
 - texture analysis, 472
 - support substantiation, 40–42, 50–52
 - COLIPA, 50
 - mind claims, 55, 58–60
 - standard operating procedures needed, 45–46
 - subject criteria, 42–45
 - types
 - body-mind claims, 52–54
 - emotive claims, 50
 - ingredient claims, 37–38, 50
 - mind claims, 55, 58–60
 - NICE (nervous, immune, cutaneous, and endocrine system) concept, 50
 - product claims, 38–40, 50
 - QoL (Quality of Life) claims, 56–58, 60
 - statement claims, 37

Cosmetic Directive
76/768/EEC, 8
Annex I, 9
Sixth Amendment, 36

cosmetics
compliance to published
monographs, 7
definition
EU, 8–9
Japan, 9–11
US, 6
New Drug Application, 7

cotton extract effects, 162–166

coumarin, 334
EU anti-dumping import duties,
334
US skin lightening patent, 332

CPDs (cyclobutane-pyrimidine
dimers), 129–130
DNA repairs for decreasing CPDs,
183–185
studies/results, 185–194
UVB formation of photoproducts,
156
cotton extract effects, 162–166
dot blot semiquantification,
161–162
immunocytofluorescence,
156–161

creatine, 112

CT (coal tar), 617–620, 621
antidandruff studies/results with
SSOS and CT, 623–631

CT (connective tissue), 570–571

cyclin-dependent kinase (CDK)
inhibitor, 123

cyclobutane pyrimidine dimers. See
CPDs

(Cys-Gly)₂ dimer peptide, 148,
151–153

cysteine proteases, 263, 264

cytotkines, 118, 119, 128, 129

cytotoxic chemicals, 30–31

D

dandruff. See antidandruff

dansyl chloride staining technique,
282

defense proteins, 118

deodorants
MDCP (myristamidopropyl PG-
dimonium chloride phosphate), 579
performance attributes with
MDCP and triclosan, 583–586
studies/results with MDMP and
triclosan, 580–583
triclosan, 578–579

deoxyabutin, 330

deoxyribonucleic acid. See DNA

DGLA (dihomo-gamma-linolenic
acid), 316

DHA (dihydroxyacetone)
exfoliation, 269–270
self-tanning formulations, 87,
92–93
disadvantages, 403
water-soluble ingredients, 84, 86

dihomo-gamma-linolenic acid
(DGLA), 316

dihydroxyacetone. See DHA

dimethyl isosorbidea. See DMI

dioic acid, 73–74, 76–77, 79–81

DMI (dimethyl isosorbidea)
self-tanning formulations, 87–93
skin delivery, 84–85
of hydrophilic actives, 85–87

DNA (deoxyribonucleic acid)
damage/repair, 129–130, 181. See
also DNAna; mtDNA; nuDNA;
sodium DNA
cell senescence, 122–123
compatible solutes, 198, 204
CPDs (cyclobutane-pyrimidine
dimers) decreases, 183–185
studies/results, 185–194

damage and repair, 171–174
example, 130–134
genome, 169–170
MMPs (matrix metalloproteinases), 128–129
NER (nucleotide excision repair)
mechanism, 161, 172
OGG1 (8-oxo-guanine glycosylase-1), 130
photoprotection, 176–177
p53/p21/p16ink4a pathway, 123–124
stimulation of, 175, 177
watermelon extract, 197–205
DNA-Na, 494–497
Draize rabbit skin test, 28–30
drugs. See OTC drugs; prescription drugs
dsRNA (short double-stranded RNAs), 21–22
 δ -tocopherols, 525

e

ECM (extracellular matrix), fibroblast interactions with, 476, 479
alpha-SMA, 478
EGCG (epigallocatechin gallate), 510
8-oxo-guanine glycosylase-1 (OGG1), 130
elastin
amino acids, 112
peptides, 111
proteins, 117
Emblica officinalis extract, 332. See also *P. embilica*
emollients, 76–77, 79
emotive claims, 50
emulsifiers
skin delivery, 80–81
skin lightening
grapefruit extract, 378–393

β -endorphin, 115
enzymes, 511–513
epigallocatechin gallate (EGCG), 510
EPO (evening primrose oil) for irritated skin, 310–319
esterfied fatty acid ceramide, 419
EU (European Union)
COLIPA (Cosmetic, Toiletry, and Perfumery Association), 50
cosmetics
definition, 8–9
REACH, 27
European Union. See EU
evening primrose oil. See EPO

f

fairness products. See skin lightening
fatty acid ceramides, 419
FDA (Food and Drug Administration)
AHAs, 8
hydroquinone ban, 374
New Drug Application, 7
OTC drugs, 7
prescription drugs, 7
fibroblasts
cell senescence, 122
DNA-Na, 494–497
ECM interactions, 476, 479
MMP-1 gene expression, 132
mutations in mtDNA, 143–146
sodium DNA, 494
fibronectin
peptides, 116
proteins, 115, 117, 118
filaggrin peptides, 242–243
fMRI (functional Magnetic Resonance Imaging), 57–59
Food, Drug and Cosmetic Act of 1938
cosmetics, 6

- OTC drugs, 7
- prescription drugs, 7
 - OTC drugs, switching to, 7
- forskolin, 400
- free radicals, 210, 212–216
- from milk, 103–104
- FTIR (Fourier-transformed infrared)
 - on IPIS and ISIS, 433, 434–436, 437
- functional Magnetic Resonance Imaging. See fMRI
- functional proteins, 117
- fusion peptides, 106–107

g

- gadd45 α gene expression, 175, 179
- GAG (glycosaminoglycans), 292–293, 570
- gamma-linolenic acid (GLA), 309–311, 316–318
- gene expression, 21
- GHK-Cu peptides, 100
- ginger extract/gingerols, 541–543
 - (-)- α -bisabolol, 543–546
- GLA (gamma-linolenic acid), 309–311, 316–318
- glutathion peroxidase (GPO), 511–513
- glutathione, 113, 511, 605–606
- glycolic acid versus PFPE phosphate studies, 280–285
 - results, 285–291
 - in vitro, 289
- glycosaminoglycans (GAG), 292–293, 570
- Gly-His-Lys (glycine, histidine and lysine), 113–114, 516
- γ -PGA (γ -poly glutamic acid), 443–446
 - cosmetic applications

- hair, 450–453
 - skin, 446–449
- γ -PGA hydrogel, 449–450, 451
- GPO (glutathion peroxidase), 511–513
- grapefruit extract, skin lightening studies
 - content measurements
 - moisture, 387–388
 - pH values, 389–390
 - sebum, 388–389
- emulsion, preparation and analysis, 378–383
- sensory evaluations, 392–393
- tests
 - dermatological, 383–384
 - erythema, 385–387
 - melanin, 384–385
- TEWL, 390–392
- green tea, 15, 510
- γ -tocopherols, 525

h

- HA (hyalauronic acid), 84, 455–456
- SHA (sodium hyaluronate), 455
- SHAB (sodium hyaluronate, fermentation of *Bacillus subtilis*), 457–458
 - antiaging properties, 460–463
 - moisturization properties, 458–460
- hair loss
 - arachidonic acid, 604, 606–610
 - CLA glutathione, 606–609
 - CLASH-DNA (CLA glutathione and sodium DNA), 609–614
 - females, 591–592
 - alopecia, 591
 - Hypericum perforatum extract, 592–593
 - t-flavanone, 594–600

glutathione, 605–606
 linoleic acid, 604
 sodium DNA, 609
 H-beta-Ala-Pro-Dab-NH-benzyl diacetate, 254–259
 hemoglobin, 117
 hexapeptides, 15, 116
 Huntington's disease, 24
 hyaluronic acid. See HA
 hydroquinone
 cosmetic use ban, 335, 374
 phyllanthus emblica, 365, 367
 tyrosinase inhibitors, 329, 340–341
 US patents, 331–333, 332, 333
 Hypericum perforatum extract, 592–593

i

Individual Typology Angle (ITA), 367–369, 371
 ingredient claims, 37–38, 50
 interferon, 118
 interleukin-1 (IL-1) and/or prostaglandin E2 (PGE2) inhibition
 (-)- α -bisabolol, 540–541
 interleukins, 118
 IPIS (isopropyl isostearate) and ISIS (isoteraryl isostearate), 428–432
 ITA (Individual Typology Angle), 367–369, 371

j

Japan
 cosmetics, 9–11
 JCIC (Japanese Cosmetic Ingredients Codex)
 proteases, 266
 quasi-drugs, 9–11

k

keratin, 112
 keratinocytes
 cell senescence, 122
 CPD (cyclobutane-pyrimidine dimers), 155
 cotton extract effects, 162–166
 dot blot semiquantification, 161–162
 immunocytofluorescence, 156–161
 DNA-Na, 494–497
 epidermal model, 29–31
 exfoliation of keratinized cells, 262–263
 gadd45 α gene expression, 175
 interleukin-1 (IL-1) and/or prostaglandin E2 (PGE2) inhibition
 (-)- α -bisabolol, 540–541
 MSE (malva sylvestris extract), effects on, 241–242
 peptides, 111
 POMC (pro-opiomelanocortin), 115
 sodium DNA, 494
 tanning without self-tanners or UV exposure, 399–402
 kit ligand, 335
 kojic acid, 330, 340–341, 347–348
 K30S (kaempferol-3-O-sophoroside), 181
 KTTKS peptides, 100–101, 106–107

l

LA (linoleic acid), 316–317, 332, 604
 lactobionic acid, 15
 lacto-peroxidase/glucose oxidase system, 118

- laminin, 117
LAP (latency-associated protein), 250–251
latency-associated protein. See LAP
licorice extract, 340
linoleic acid (LA), 316–317, 332, 604
lipid peroxidation, 148–149, 153
lipoproteins, 117
liposome delivery, 129–130
LKKTET polypeptides, 100
lysophosphatidylethanolamine, 336
- m**
mallow extract. See MSE
malva sylvestris extract. See MSE
mast cell growth factor, 335
matrix metalloproteinases (MMPs), 128–129, 570
MC1R (melanocortin-1 receptor), 404
MDCP (myristamidopropyl PG-dimonium chloride phosphate), 579
 performance attributes with MDCP and triclosan, 583–586
 studies/results with MDCP and triclosan, 580–583
mechano-receptors and alpha-SMA, 477–479
melan-c cell line
 tyrosinase inhibitors, 346–349
melanin, 329
 ascorbic acid, 330
 black melanin reduction, 328
 grapefruit extract in emulsions, 384–385
 hydroquinone, 329
 leuco-melanin, 330, 331
 niacinamide, 327
 Phyllanthus embilica, 364, 365–373
 skin damage prevention, 511
 synthesizing, 404–405
 tyrosine-melanin reduction enzymes, 331
melanocortin. See MSH
melanocortin-1 receptor (MC1R), 404
melanocytes. See also tyrosinase inhibitors
 B16 melanocytes, 345–346, 347
 PEAS and actives, efficacy, 354–358
 melanin, manufacturing, 384
 MSH (melanocyte stimulating hormones), 400
 pigment transfer to keratinocytes, 404
 inhibiting, 330
 tanning without self-tanners or UV exposure, 399–402
melanogenesis stage, pigment formation, 330. See also tyrosinase inhibitors
 extracts suppressing, 336
 songyi mushroom extract, 331
melanosomes, 404–405
menthol and mint, 637–639
mesotherapy, 572–573
messenger RNA. See mRNA
microcirculation, 569–570
milk casein, 112
mind claims, 55, 58–60
 mind-body claims, 52–54
minimal erythema dose (MED), 220–221
Ministry of Health and Welfare, Japan, 9
miRNA (microRNAs), 21–25
mitochondria
 mitochondrial DNA (See mtDNA)
 structure and function, 139–140
MMP-1 (collagenase-1), 128, 132
MSE (mlva sylvestris extract), 243–244

MMPs (matrix metalloproteinases),
128–129, 570
morus alba L extract, 340–341
mRNA (messenger ribonucleic acid),
170
cleavage and degradation, 21–24
RT-PCR
analysis, 350
and coding for filaggrin, 241
MSE (malva sylvestris extract)
dermal metabolism, 242–246
extracellular matrix degradation,
243–244
epidermal metabolism, 240–241
keratinocyte differentiation,
241–242
MSH (melanocortin), 115
MSH (melanocyte stimulating
hormones), 400
mtDNA, 181. See also DNA;
mitochondria; nuDNA
CoQ10 (coenzyme Q10), 141–146
mutations in fibroblasts, 143–146
versus nuDNA, 141
premature skin aging, 142
ROS (reactive oxygen species),
140–141, 170
RT-PCR (real time polymerase
chain reaction), 143–146
MTT, 29–31
mulberroside A
biological activities
with *Morus alba* extract, 343–
348, 350–352
with oxyresveratrol, 342–350
identification of, 341–342
murine tyrosinase, 343–345
myoglobin, 117, 118
myosin, 117
myristamidopropyl PG-dimonium
chloride phosphate. See MDCP

n
nanoemulsion, CoQ10 and vitamin E
acetate, 143–146
natto gum. See γ -PGA
natural moisturizing factor (NMF),
112
NDA (New Drug Application), 7
near-infrared reflectance spectroscopy.
See NIR
NER (nucleotide excision repair), 161,
172, 181
neuroscience
mind and body links, 52
niacin, 330, 333
niacinamide, 327, 330, 333
NICE (nervous, immune, cutaneous,
and endocrine system) concept, 50
NIR (near-infrared reflectance)
spectroscopy on IPIS and ISIS,
439
versus Corneometer measurements,
428–432
NMF (natural moisturizing factor),
112
normal fatty acid ceramide, 419
nucleotide excision repair (NER), 161
nuDNA (nuclear deoxyribonucleic
acid), 181
BER (base excision repair), 172
comet assay on human
keratinocytes, 174
versus mtDNA, 141

o
octadecenedioic acid. See dioic acid
OECD (Organization for Economic
Co-Operation and Development),
29
OGG1 (8-oxo-guanine glycosylase-1),
130
oligopeptides, 111, 113, 115

- omega hydrofatty acid ceramide, 419
- OTC (over the counter) drugs
definition, 7
prescription drugs, switching from, 7
- 8-oxo-guanine, 197–198, 200
- oxytocin, 113
- p**
- P. emblica* (*phyllanthus emblica*), 364.
See also *emblica officinalis*
hydrolyzable tannins, 364
mechanism of melanin inhibitory actions, 372–373
skin lightening studies, 365–368, 369–370
with hydroquinone, 365, 367
on hyperpigmented skin, 368–369, 371–372
on normal skin, 370–371
- p53 protein, 198
- packaging. See cosmetic claims
- pain management, 25
- Pal-GHK, 116, 517
- Pal-GQPR peptide, 517
- Pal-KTTKS peptide, 516
- Pal-KTTKSb,b,4-5, 116
- palmitoyl tripeptide-5, 250–254
- Palm-Lys-Val-Lys-OH tripeptide, 250–254
- pea extract and sucrose dilaurate. See PEAS
- PEAS (pea extract and sucrose dilaurate), 354
tyrosinase inhibitors
PEAS and actives, efficacy, 354–358
PEAS and hydroquinone in emulsions, 359–361
- pentapeptides
antiaging, 15
Pal-KTTKSb,b,4-5, 116
- peptides, 99–100. See also hexapeptides; oligopeptides; pentapeptides; polypeptides; tetrapeptides; tripeptides
- alpha-S2 casein precursor, 103
- antiaging products, 99–100
- cell senescence, 102
- in cosmetics, 112–117
(Cys-Gly)₂ dimer, 148, 151–153
definition, 110
flaggrin, 242–243
fusion, 106–107
GHK-Cu, 100
γ-PGA (γ-poly glutamic acid), 443–446
cosmetic applications, 446–453
γ-PGA hydrogel, 449–450, 451
- KTTKS, 100–101, 106–107
- manufacturing, 111
- origin, 111
- Pal-GHK, 517
- Pal-GQPR, 517
- Pal-KTTKS, 516
- Pal-KTTKSb,b,4-5, 116
- Tat peptides, 106
- thymosin beta4, 104
- perfluoropolyether phosphate. See PFPE phosphate
- peroxidase, 369, 372
- PFPE phosphate versus glycolic acid
results, 285–291
studies, 280–285
in vitro, 289
- PG (proteoglycans), 292–293
- pharmaceuticals and cosmetics, 6
- photo-aging
clinical studies, 130–133
DNA repair enzymes, 129–130
MMPs (matrix metalloproteinases), 128–129
wrinkling, 128
- photoprotection, 16
- phyllanthus emblica*. See *P. emblica*
- phytosphingosine ceramide, 419

phytosterols, 211, 215, 524–525
polypeptides
 LKKTET, 100
POMC (pro-opiomelanocortin), 115
 β -endorphins, 405–406
 α -MSH (α -melanocyte-stimulating hormone), 405, 406
p53/p21/p16ink4a pathway, 123–124
prescription drugs
 definition, 7
 OTC drugs, switching to, 7
product claims. See cosmetic claims
pro-opiomelanocortin (POMC), 115
proteases
 aspartic proteases, 263
 cysteine proteases, 263, 264
 in facial cleaners, 265–266
 kertinized cell exfoliation, 262–263
 SC (stratum corneum), 263–265
 serine proteases, 263, 264, 265
 CL-SB (cross-linking subtilisin),
 267–269, 273–275
 subtilisin, 266
 subtilisin monomer, 268–269,
 273–274
 stability, 273–275
protein carbonylation, 149, 151–152
proteins
 in cosmetics, 117–119
 definition, 110
 manufacturing, 111
 origin, 111
 p53 protein, 198
 peptides, 111
 sirtuin proteins, 231–232
proteoglycans (PG), 292–293
proteolytic enzymes, 119, 122
purple formazan crystals, 30

q

QoL (Quality of Life) claims, 56–58,
60
qRT-PCR (quantitative RT-PCR),
175, 177, 181
QSARs (quantitative structure-
activity relationship) analysis, 28
quasi-drugs, Japan, 9–11

r

REACH (Registration, Evaluation
and Authorization of Chemicals),
27–28
reactive oxygen species. See ROS
Registration, Evaluation and
Authorization of Chemicals. See
REACH
resorcinol derivative, 332, 335
retinoids, 14, 15
retinoids/retinoic acid, 240, 242–246
reverse transcriptase polymerase chain
reaction. See RT-PCR
RGS amino acids, 104–105
rice bran extract, 211–216
RISC (RNA Interference Silencing
Complex), 21–23
RNA (ribonucleic acid), 181. See also
dsRNA; miRNA; mRNA; RISC;
RNAi; shRNA; siRNA
 molecule delivery to targets, 25
RNAi (RNA interference), 21–22
 in therapeutics, 23
 challenges, 25–26
 pain management, 25
 spinal cord injuries, 25
ROS (reactive oxygen species), 140–
141, 170
 free radicals, 210, 212–216

- rice bran extract creams,
 - microscopy on effects of, 212–216
 - skin aging, 210
 - protecting against, 211–212, 511
- RPI (Relative Polarity Index), 70–76
 - experiments, 76–81
- RSV (respiratory syncytial virus), 24–25
- RT-PCR (reverse transcriptase polymerase chain reaction), 131, 181
 - Cdel (common deletion), 143–144, 174
 - mRNA coding for filaggrin, 241
 - tyrosinase mRNA analysis, 350–352
- Rumex acid, 330
- rye extract, 479–488
- S**
- SA-b-gal (senescence-associated b-galactosidase) enzyme, 124–125
- SAE (senna alata extract), 172–179, 181
- salicylic acid, 15
- SAXD (small angle X-ray diffraction)
 - human and synthetic SC lipids, 419, 421–422
 - on IPIS and ISIS, 433–434
- SC (stratum corneum), 226
 - capacitance, 221, 224, 225
 - epidermal model, 29
 - Maillard reaction, 268
 - proteases, 263–265
 - CL-SB (cross-linking subtilisin), 266, 267–269, 273–275
 - in facial cleaners, 265–266
- SCTT (stratum corneum turnover time)
 - dansyl chloride staining technique, 282, 284
 - PFPE and glycolic acid, 284–286, 288
 - studies of lipids in multi-lamellar systems, 419–425
- SCF (stem cell factor), 336
- selective sirtuin-activating compound (STACs), 233–234
- self-tanning products/processes, 87–93
 - β -endorphins, 405–406
 - chaste tree berry extracts
 - acetyl tyrosine, 407–412
 - β -endorphin-like compounds, 406–407
 - DHA disadvantages, 403
 - melanin synthesis, 404–405
 - tanning without self-tanners, 399–401
- senescence-associated b-galactosidase (SA-b-gal) enzyme, 124–125
- senna alata extract (SAE), 172–179, 181
- sequence-specific post-transcriptional gene silencing
 - dsRNA (short double-stranded RNAs), 21–22
 - miRNA (microRNAs), 21–23
 - in therapeutics, 23–25
 - mRNA cleavage and degradation, 21–24
 - RISC (RNA Interference Silencing Complex), 21–23
 - RNAi (RNA interference), 21–22
 - in therapeutics, 23–25
 - siRNA (small interfering RNAs), 21–23
 - in therapeutics, 23–25
- serine proteases, 263, 264, 265
 - CL-SB (cross-linking subtilisin), 267–269, 273–275
- SHA (sodium hyaluronate), 455
- SHAB (sodium hyaluronate, fermentation of *Bacillus subtilis*), 457–458
 - antiaging properties, 460–463

- moisturization properties, 458–460
- shRNA (short hairpin RNA), 24
- signaling proteins, 118
- SIPS (Stress-induced Premature Senescence), 123
- siRNA (small interfering RNAs), 21–23
 - in therapeutics, 23
 - APoB protein silencing, 24
 - challenges, 25–26
 - drug safety, 24
 - Huntington's disease, 24
 - pain management, 25
 - spinal cord injuries, 25
 - viral infections, 24–25
- sirtuin proteins, 231–232
 - in cell cycles, 234–235
 - SIRT1 expression in skin, 232–233
 - protective role, 235–236
 - STACs (selective sirtuin-activating compound), 233–234
- skin aging. See antiaging process/products
- skin anti-irritants/anti-itch
 - (-)- α -bisabolol, 540–541
 - ginger extract/gingerols, 541–546
 - avenanthramides
 - natural: A, B and C, 550–551
 - synthetic, 551–552
 - synthetic, studies/results, 552–563
 - interleukin-1 (IL-1) and/or prostaglandin E2 (PGE2) inhibition, 540–541
- skin cooling processes/products
 - cooling action
 - physiology, 642–645
 - on skin, 646–648
 - strength, 645
 - menthol and mint, 637–639
 - synthetics, 639–642
 - patents, 648–650
 - products, 650–652
 - warming action
 - physiology, 642–645
- skin corrosion potential
 - animal testing, 28
 - alternatives, 28–31
 - Draize rabbit skin test, 28–30
 - OECD, 29–30
 - REACH regulations, 27–28
- skin delivery, 66–69
 - DHA (dihydroxyacetone)
 - self-tanning formulations, 87, 92–93
 - water-soluble ingredients, 84, 86
 - dimethyl isosorbide, 83–84
 - DMI (dimethyl isosorbide), 84–85
 - of hydrophilic actives, 85–87
 - self-tanning formulations, 87–93
 - influence of formulation characteristics, 69–70
 - RPI (Relative Polarity Index), 70–76
 - experiments, 76–81
- skin lightening. See also tyrosinase inhibitors
 - India, 327–330, 334–335
 - cosmetic and toiletries companies, ranked, 326
 - market, 326–327, 336
 - regulations, lack of, 335
 - melanin, 329
 - ascorbic acid, 330
 - black melanin reduction, 328
 - emulsifiers with grapefruit extract, 378–393
 - hydroquinone, 329

- leuco-melanin, 330, 331
- niacinamide, 327, 330, 333
- Phyllanthus emblica*, 363–373
- tyrosinase inhibitors, 329–331, 334
- United States, patents, 332–333, 335–336
- skin structure
 - body contouring, 567–568
- skin tightening claims, 469–473, 470.
 - See also antiaging process/products
 - clear gel, 471–472
 - indentometric testing, 470–473
 - texture analysis, 472
- skin whiteners/brighteners. See skin lightening
- slimming. See body contouring
- small angle X-ray diffraction. See SAXD
- SNAP amino acids, 105–106
- SOD (superoxide dismutase) and UV radiation
 - damage prevention, 511–513
 - oxidative stress, 147–149, 151
- sodium DNA, 493–494
 - body creams, 498
 - emulsions, 497, 499
 - hair loss
 - CLA glutathione, 609–610
 - CLASH-DNA (CLA glutathione and sodium DNA), 609–614
 - keratinocytes and fibroblasts, 494
- sodium shale oil sulfonate. See SSOS
- songyi mushroom extract, 330, 331
- sphingosine ceramide, 419
- spinal cord injuries, 25
- SSOS (sodium shale oil sulfonate), 618, 620–623
 - antidandruff studies/results with
 - SSOS and CT, 623–631
- STACs (selective sirtuin-activating compound), 233–234
- statement claims, 37
- stem cell factor (SCF), 336
- Strecker method¹, 110
- Stress-induced Premature Senescence (SIPS), 123
- structural proteins, 117
- subtilisin, 266
- subtilisin monomer, 268–269, 273–274
- sunscreens/sun care products. See also self-tanning products/processes; tanning products/processes
- antiaging, 507
 - γ - and δ -tocopherols, 525
 - phytosterols, 524–525
 - α -tocopherols, 524–525
- antiaging actives, 506–507
 - damage prevention, 507–513
 - UV-induced age symptoms, treatments, 513–517
- canola oil, 523–524, 525
- COLE (canola oil liquid emollient), 525
 - anti-inflammation properties, 530
 - oxidation stability, 525–526
 - protection against photooxidation, 526–530
 - sun care examples, 530–532
- Proposed Rules for Sunscreens, 8
- sunscreens
 - definition, 505–506
 - formulations, 517–518
- superoxide dismutase. See SOD
- syndecan-1
 - GAG (glycosaminoglycans), 292–293
 - PG (proteoglycans), 292–293

studies, epidermis cohesion on
syndecan-1 with AcTP11, 296–
298, 301–303
 results, 298–301

t

tanning products/processes. See also
 self-tanning products/processes;
 sunscreens/sun care products
 without self-tanners or UV
 exposure, 399–402

tannins, 364

Tat peptides, 106

taurine, 112

telomere shortening, 122–123

tetrahydrocurcuminoids, 334

tetrapeptides, AcTP11, 295–296

 studies/results, epidermis cohesion
 on syndecan-1 and type XVII
 collagen, 296–301, 301–303

t-flavanone, 594–600

TGF-beta (transforming growth
 factor beta) activation, 250–252

therapeutics, 21

3-(4,5-dimethylthiazol-2-yl)-2,
 5-diphenyltetrazolium bromide.
 See MTT

thrombospondin-1. See TSP

thymosin beta4 peptides, 104

titanium dioxide

 micronized, 15

tocopherols, 211–212, 215, 508

tocotrienols, 211–212, 215

transferrine, 117

tretinoin, 14

triclosan, 578–579

 performance attributes with
 MDCP and triclosan, 583–586
 studies/results with MDCP and
 triclosan, 580–583

tripeptides

 Gly-His-Lys (glycine, histidine and
 lysine), 113–114, 516

H-beta-Ala-Pro-Dab-NH-benzyl
 diacetate, 254–259

Pal-GHK, 116

palmitoyl tripeptide-5, 250–254

Palm-Lys-Val-Lys-OH tripeptide,
 250–254

TSP (thrombospondin-1), 250–251
 tumeric, 334

two-photon fluorescence microscopy,
 212–216

type XVII collagen, 295

 studies, epidermis cohesion on
 type XVII collagen with AcTP11,
 296–298, 301–303
 results, 298–301

tyrosinase inhibitors. See also

 melanogenesis stage, pigment
 formation; skin lightening

 arbutin, 329–330, 340, 347–348

 ascorbic acid, 330, 340

 deoxyabutin, 330

 extracts, 336

 hydroquinone, 329, 340–341

 kojic acid, 330, 340–341, 347–348

 licorice extract, 340

 Morus alba extract, 343–348,
 350–352

 Morus alba L, 340–341

 with mulberroside and

 oxyresveratrol, 342–352

 P. emblica, 369, 372

 PEAS

 and actives, efficacy, 354–358

 and hydroquinone in emulsions,
 359–361

 tetrahydrocurcuminoids, 334

u

UK (United Kingdom)

 Advertising Standards Association,
 40

 Broadcast Advertising Clearance
 Centre, 40

- urocanic acid, 511
 - US FDA (Food and Drug Administration)
 - AHAs, 8
 - hydroquinone ban, 374
 - New Drug Application, 7
 - OTC drugs, 7
 - prescription drugs, 7
 - UV (ultraviolet) radiation
 - CPDs (cyclobutane-pyrimidine dimers)
 - DNA repairs for decreasing, 183–185
 - DNA repairs for decreasing, studies/results, 185–194
 - inhibiting erythema with emulsions
 - clinical studies, 220–226
 - mtDNA, mutations in fibroblasts, 143–146
 - oxidative stress
 - BCA assay (bicinchoninic acid assay), 150
 - catalase, 147–149, 151–152
 - lipid peroxidation, 148–149, 153
 - protein carbonylation, 149, 151–152
 - SOD (superoxide dismutase), 147–149, 151
 - 8-oxo-guanine, 197–198, 200
 - photo-aging
 - clinical studies, 130–133
 - DNA repair enzymes, 129–130
 - MMPs (matrix metalloproteinases), 128–129
 - wrinkling, 128
 - rice bran extract formulas, 213, 215
 - tanning alternative to UV radiation, 399–401
 - UVA radiation
 - DNA damage/repair, 171–172
 - oxidative damage, 160
 - photoprotection, 16
 - protection against, 174
 - studies/results, 176–180
 - toxicity, 170–171
 - UVB radiation
 - barrier repair, 514–515
 - CPD (cyclobutane-pyrimidine dimers), 155
 - cotton extract effects, 162–166
 - dot blot semiquantification, 161–162
 - immunocytofluorescence, 156–161
 - NER (nucleotide excision repair) mechanism, 161
 - DNA damage/repair, 171–172
 - photoproducts, 155
 - studies/results, 176–180
 - toxicity, 170–171
 - UVC effects, 160
- V**
- vanillin, 333
 - vasopressin, 113
 - vinculin and alpha2beta1 integrins, 481, 484
 - viral infections, 24–25
 - vitamin C, 330, 340, 508
 - vitamin E
 - antiaging, 15, 508
 - inhibiting erythema with emulsions
 - with/without
 - clinical studies, 220–226

W

- watermelon extract, 197–205
- wheat gluten, 112
- WHO (World Health Organization)
 - definition of health, 56
- wrinkle reduction. See antiaging
 - process/products

X

- xanthines and derivatives, 571

Y

- yohimbine, 331, 332, 333

Z

- zinc oxide, microfine, 15